PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

por Fujita, T, Doihara, H, Kawasaki, K, Takabatake, D, Takahashi, H, Washio, K, Tsukuda, K, Ogasawara, Y, Shimizu, N
Publicado 2006

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2

por Kunisue, H, Kurebayashi, J, Otsuki, T, Tang, C K, Kurosumi, M, Yamamoto, S, Tanaka, K, Doihara, H, Shimizu, N, Sonoo, H
Publicado 2000

Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT...

por Shiroiwa, T., Fukuda, T., Shimozuma, K., Mouri, M., Hagiwara, Y., Doihara, H., Akabane, H., Kashiwaba, M., Watanabe, T., Ohashi, Y., Mukai, H.
Publicado 2016